



News Release

Suven Secures 8th product patent Both in Australia and Mexico

HYDERABAD, INDIA (Sep 8, 2010) – Suven Life Sciences Ltd (SUVEN) announces today that a product patent was granted in Australia (**2003285759**) and in Mexico (**276592**) for one of their new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2023 and 2025 respectively.

The granted claims of the patents include the class of **selective 5-HT compounds discovered by Suven** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as **Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.**

With these new patents, Suven has a total of Eight (8) granted product patents **for their NCEs in CNS therapy both in Australia and Mexico.** These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions **may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.**

"We are very pleased by the grant of these patents to Suven by the patent offices of Australia and Mexico for **our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated \$30 billion market potential globally**" says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates currently** in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information on Suven please visit our Web site at <http://www.suven.com>

Safe Harbor Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

In Search of new CNS therapies for better living

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com